Literature DB >> 30917378

Laparoscopic Hepatectomy (with or without Robotic Assistance) versus Radiofrequency Ablation as a Minimally Invasive Treatment for Very Early-Stage or Early-Stage Hepatocellular Carcinoma.

Charing Ching-Ning Chong1, Kit-Fai Lee2, Cheuk-Man Chu3, Anthony Wing-Hung Chan4, Simon Chun-Ho Yu3, Paul Bo-San Lai2.   

Abstract

BACKGROUND: The advantages of radiofrequency ablation (RFA) over hepatectomy as a treatment for early-stage hepatocellular carcinoma (HCC) include reduced morbidity and more rapid recovery. Although minimally invasive surgery provides similar benefits, few studies have compared the long-term oncological outcomes of these techniques. This study aimed to compare the outcomes of minimally invasive hepatectomy (MIH) and RFA.
METHODS: Patients who underwent MIH or RFA for HCC between January 2005 and January 2015 were included in a propensity score matching analysis. Only patients who underwent minimally invasive procedures for small HCC were included. Baseline clinical and laboratory parameters were retrieved from the hospital database and analyzed.
RESULTS: Two hundred and twenty-five patients underwent MIH or RFA for HCC during the study period. Propensity score matching yielded 59 patient-pairs. The complication rates did not differ statistically between the 2 groups (p = 0.309). However, MIH provided significantly better overall (p = 0.005) and disease-free survival outcomes (p < 0.001) than RFA.
CONCLUSIONS: Compared with RFA, MIH provided better long-term survival outcomes in patients with early-stage HCC, with no increase in the incidence of complications. When feasible, MIH should be considered a first-line treatment for this patient population.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Hepatocellular cancer; Laparoscopic surgery; Liver resection; Liver surgery; Minimally invasive surgery; Radiofrequency ablation; Robotic surgery

Year:  2019        PMID: 30917378     DOI: 10.1159/000497112

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  6 in total

1.  Laparoscopic Versus Open Surgery for Early-Stage Intrahepatic Cholangiocarcinoma After Mastering the Learning Curve: A Multicenter Data-Based Matched Study.

Authors:  Yang Jinhuan; Wang Yi; Zheng Yuanwen; Ma Delin; Chen Xiaotian; Wang Yan; Deng Liming; Yu Haitao; Wu Lijun; Deng Tuo; Chen Kaiyu; Hu Jiawei; Zheng Chongming; Wang Daojie; Jin Bin; Chen Gang
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

2.  Efficacy of radiofrequency ablation versus laparoscopic liver resection for hepatocellular carcinoma in China: a comprehensive meta-analysis.

Authors:  Zhijun Li; Qiong Yu; Xiaozheng Lu; Yahui Liu; Bai Ji
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-04-14       Impact factor: 1.195

Review 3.  Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis.

Authors:  Sha Yang; Huapeng Lin; Jianning Song
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

4.  Pure laparoscopic liver resection versus percutaneous radiofrequency ablation for small hepatocellular carcinoma: a propensity score and multivariate analysis.

Authors:  Kai-Chi Cheng; Kit-Man Ho
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

5.  Period-Dependent Survival Benefit of Percutaneous Microwave Ablation for Hepatocellular Carcinoma: A 12-Year Real-World, Multicentric Experience.

Authors:  Jie Yu; Zhi-Gang Cheng; Zhi-Yu Han; Fang-Yi Liu; Rong-Qin Zheng; Wen Cheng; Qiang Wei; Song-Yuan Yu; Qin-Ying Li; Guang-Zhi He; Yan-Chun Luo; Xiao-Ling Yu; Ping Liang
Journal:  Liver Cancer       Date:  2022-01-28       Impact factor: 12.430

6.  The effects of ultrasound-guided radiofrequency ablation and laparoscopic hepatectomy in the treatment of small hepatocellular carcinoma: a retrospective analysis.

Authors:  Haishan Xu; Ling Zhou; Qicheng Jin
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.